Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
dc.contributor.author | Wolleschak, Denise | |
dc.contributor.author | Mack, Thomas S | |
dc.contributor.author | Perner, Florian | |
dc.contributor.author | Frey, Stephanie | |
dc.contributor.author | Schnöder, Tina M | |
dc.contributor.author | Wagner, Marie-Christine | |
dc.contributor.author | Höding, Christine | |
dc.contributor.author | Pils, Marina C | |
dc.contributor.author | Parkner, Andreas | |
dc.contributor.author | Kliche, Stefanie | |
dc.contributor.author | Schraven, Burkhart | |
dc.contributor.author | Hebel, Katrin | |
dc.contributor.author | Brunner-Weinzierl, Monika | |
dc.contributor.author | Ranjan, Satish | |
dc.contributor.author | Isermann, Berend | |
dc.contributor.author | Lipka, Daniel B | |
dc.contributor.author | Fischer, Thomas | |
dc.contributor.author | Heidel, Florian H | |
dc.date.accessioned | 2014-08-21T10:32:29Z | en |
dc.date.available | 2014-08-21T10:32:29Z | en |
dc.date.issued | 2014-06 | en |
dc.identifier.citation | Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. 2014, 99 (6):e90-3 Haematologica | en |
dc.identifier.issn | 1592-8721 | en |
dc.identifier.pmid | 24633870 | en |
dc.identifier.doi | 10.3324/haematol.2014.104331 | en |
dc.identifier.uri | http://hdl.handle.net/10033/325037 | en |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Haematologica | en |
dc.title | Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. | en |
dc.type | article | en |
dc.identifier.journal | Haematologica | en |
refterms.dateFOA | 2018-06-12T19:59:05Z |